Brind.

Tempus AI and NeoGenomics completed an acquisition to strengthen AI leadership in healthcare.

1 report, 1 independent Updated Aug 26

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Tempus NeoGenomics

How it developed

Newest first. Tap a step to see who reported it.

Jun 7Tempus AI is accelerating foundation model development by utilizing digital slide archives from Memorial Sloan Kettering Cancer Center and Microsoft Azure.Sub-event
Aug 26Acquisition between Tempus AI and NeoGenomics boosts AI healthcare capabilities.1 source
- Zacks

Keep exploring

The entities involved

Tempus
biotechnology company based in Chicago, Illinois
- Tempus is scheduled to participate in a conference in New York City on September 4, 2025.Sun 01:41
- Tempus AI, led by Eric Lefkofsky, is acquiring Paige to enhance its digital pathology datasets.Sat 00:42
NeoGenomics
cancer genetics diagnostic testing company based in Fort Myers, Florida, USA
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44

Coverage

Newest first; wire copies grouped

Aug 26ZacksTempus' Key Acquisitions Strengthen Its AI Healthcare Leadership Last Friday, Tempus AI, Inc. TEM announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition,